SciBase Expands in the U.S. with Dermatology Practices for Skin Cancer Detection

SciBase's Continued U.S. Expansion: A Focus on Skin Cancer Detection

In a significant move towards enhancing healthcare for skin cancer patients, SciBase Holding AB, a forefront provider of augmented intelligence solutions for dermatology, has announced the onboarding of several dermatology practices across the United States. This development is part of SciBase's mission to expand access to their innovative Nevisense testing platform, which plays a crucial role in skin cancer detection, particularly melanoma.

The integration of these dermatology practices underscores SciBase's commitment to improving patient outcomes and empowering clinicians with advanced diagnostic tools. Dr. Michael McPhee, a surgical oncologist and managing director of the Melanoma Clinic in Orlando, Florida, emphasizes the paramount importance of early detection, stating that "the Nevisense test provides us the point-of-care capability in diagnosing melanoma at the earliest possible stage. Early-stage melanoma is almost 100% curable, making this advancement critical for patient survival."

Melanoma, recognized as the deadliest type of skin cancer, poses a serious risk, with approximately 20 lives lost daily in the U.S. due to this disease. The gravity of early detection cannot be overstated, as survival rates drastically increase when the cancer is identified before it advances.

Despite the advancements in dermatological practices, evaluating atypical moles remains a challenging task, even for seasoned dermoscopists. Dr. Alison Z. Young, a dermatologist and dermatopathologist based in Seattle, highlights that early-stage melanomas can display subtle physical characteristics, complicating the assessment process. The Nevisense test, being non-invasive, provides essential cellular data from beneath the skin surface, which significantly aids in managing atypical moles and in making informed biopsy decisions.

SciBase's overarching goal is to bolster the capabilities of healthcare professionals, enhancing diagnostic accuracy, facilitating early intervention, and enabling effective disease monitoring for skin cancers and other dermatological disorders. CEO Pia Renaudin expresses pride in supporting passionate clinicians like Dr. McPhee and Dr. Young, who are deeply invested in the welfare of their patients diagnosed with skin cancer.

The Nevisense platform, developed from over two decades of research conducted at the esteemed Karolinska Institute in Stockholm, Sweden, represents a leap forward in dermatology. This unique point-of-care device incorporates artificial intelligence (AI) and advanced electrical impedance spectroscopy (EIS) technology to improve diagnostic precision, thus fostering proactive management of skin health.

SciBase is not just a technology provider but a pioneer committed to minimizing patient suffering and enhancing quality of care through timely detection and intervention, ultimately reducing healthcare costs associated with late-stage cancer treatment.

Through partnerships with U.S. dermatology practices, SciBase aims to make the Nevisense test accessible to a broader patient population, addressing the pressing need for effective screening tools in the quest to combat skin cancer.

For more information, please reach out to Pia Renaudin, CEO, at +46732069802 or via email at email protected]. To learn more about SciBase and their innovative solutions, visit [www.scibase.com.